CVM

CEL-SCI Corporation
CAPPED RATING

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI Corporation (CVM) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.2
EV / EBITDA -1.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -4.7%
Price Return 12M -80.0%
Catalyst Signal 0.00
Market Cap $24.8M
TTM Revenue N/A
Price / Sales N/A
ROE -252.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D- (0.9) C- (1.9) B (3.2) C+ (2.6) C (2.2)
2026-11-04 C+ (2.5) D- (0.9) C- (2.0) B- (3.1) C+ (2.7) C (2.2)
2026-10-28 C+ (2.5) D- (1.0) C- (2.0) C (2.2) C+ (2.7) C- (2.1)
2026-10-21 C+ (2.5) D- (1.0) C- (1.9) C- (2.1) C+ (2.6) C- (2.0)
2026-10-14 C+ (2.5) D- (1.0) C- (1.9) C- (2.0) C+ (2.6) C- (2.0)
Page 1 of 3